Abzena plc

Healthcare
Early Stage
2008

Abzena offers product specific licences and services for the application of conjugation and polymer technologies to enable the development of better biopharmaceuticals through its wholly owned subsidiaries Polytherics and Antitope.

We were originally the lead investor in Warwick Effect Polymers Limited, which PolyTherics Limited acquired in 2012. Polytherics later acquired Antitope and rebranded as Abzena in 2014.

Abzena (ABZA) successfully floated on the London AIM at a valuation of £78m on 10 July 2014 at which time all institutional shareholders were 'locked in' for at least 12 months.

Our Approach

What do we look for?

Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.

We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors.

learn more

Our Team

Nick Wright

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
Enderby
Leicester
LE19 4XT

Tel: 0116 238 8200

email